NEWARK, Del., January 31, 2019 — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce MedImmune, a member of the AstraZeneca Group, Pfizer Inc., and Sartorius have joined the Institute as members.
MedImmune, the global biologics research and development arm of AstraZeneca, is an industry leader in biologics research and development. The company’s research focuses on innovative treatments in four key therapeutic areas: oncology; respiratory; cardiovascular, renal and metabolic disease; and infection vaccines. MedImmune’s robust development portfolio currently includes more than 120 biologic products.
As one of the leading biopharmaceutical manufacturers in the world, Pfizer specializes in products focused on five key therapeutic areas: internal medicine, inflammation & immunology, oncology, rare disease, and vaccines. It’s extensive R&D portfolio includes cutting-edge research on the emerging treatments of tomorrow such gene therapy and precision medicines. Pfizer brings a strong history of collaboration that will strengthen the NIIMBL community.
The Sartorius Group is a leading pharmaceutical and laboratory equipment provider with a broad product portfolio focusing on single-use solutions to support customers produce biologics and vaccines safely and efficiently. The company provides a wide-range of solutions for numerous biopharmaceutical product types including monoclonal antibodies, vaccines, blood and plasma products, bioconjugates, and biosimilars. It’s extensive knowledge of process development equipment and innovative solutions promises to benefit the NIIMBL community.
“We are excited to have MedImmune, Pfizer, and Sartorius join our membership community,” said NIIMBL Institute Director, Kelvin Lee. “The engagement of these three industry-leading companies will enhance the work NIIMBL is doing to develop new, innovative biopharmaceutical manufacturing technologies”
With 113 members from industry, academia, and non-profits, NIIMBL continues to engage the biopharmaceutical community to facilitate innovative technologies that will bring safe, efficacious products to market faster and with reduced costs.
Recently, the Institute announced a grant from the Bill & Melinda Gates Foundation to establish a Global Health Fund. The Global Health Fund will enable leading subject matter experts from NIIMBL member organizations to develop new technologies that reduce the cost of manufacturing biopharmaceuticals.
In addition, NIIMBL recently announced $13M in funding for its latest set of technology and workforce development projects.
For more information on how your organization can join the NIIMBL community, please visit http://www.niimbl.org.
NIIMBL is a public-private partnership with the goal of advancing innovation in biopharmaceutical manufacturing. NIIMBL is part of Manufacturing USA®, a network of 14 manufacturing institutes across the country that brings together industry, academia, and the public sector to propel promising research developments, accelerate new products to market, and train tomorrow’s workforce in order to secure America’s future. NIIMBL is funded through a cooperative agreement with the National Institute of Standards and Technology (NIST) in the U.S. Department of Commerce and leverages additional support from industry, academic institutions, non-profit organizations, and state governments. The NIIMBL mission is to accelerate biopharmaceutical innovation, support the development of standards that enable more efficient and rapid manufacturing capabilities, and educate and train a world-leading biopharmaceutical manufacturing workforce, fundamentally advancing U.S. competitiveness in this industry.
Contact: Daniel Maiese, Communications Manager
Follow NIIMBL on social media.